サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1413446

統合失調症治療薬市場：治療クラス、投与法、流通チャネル別-2024-2030年の世界予測

Schizophrenia Therapeutics Market by Therapeutic Class (Second Generation, Third Generation), Administration (Injectable, Oral), Distribution Channel - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 192 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
統合失調症治療薬市場：治療クラス、投与法、流通チャネル別-2024-2030年の世界予測
出版日: 2024年01月16日
発行: 360iResearch
ページ情報: 英文 192 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

統合失調症治療薬市場規模は2023年に78億9,000万米ドルと推計され、2024年には80億8,000万米ドルに達し、CAGR 4.94%で2030年には110億6,000万米ドルに達すると予測されます。

統合失調症治療薬の世界市場

主な市場の統計
基準年[2023］ 78億9,000万米ドル
予測年[2024] 80億8,000万米ドル
予測年 [2030] 110億6,000万米ドル
CAGR（%） 4.94%
統合失調症治療薬 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは統合失調症治療薬市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、統合失調症治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-統合失調症治療薬市場の市場規模および予測は？

2-統合失調症治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-統合失調症治療薬市場における技術動向と規制の枠組みは？

4-統合失調症治療薬市場における主要ベンダーの市場シェアは？

5-統合失調症治療薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界中で統合失調症の有病率が増加
      • 精神的健康状態に関する意識を高めるための政府の取り組みとキャンペーン
      • 統合失調症に対する効果的な治療薬の開発に向けた調査が進行中
    • 抑制要因
      • 高額な治療費と保険適用外
    • 機会
      • 統合失調症患者の薬効を改善するための個別化医療への注目が高まっている
      • 統合失調症の治療と治療法の進歩
    • 課題
      • 統合失調症に処方された薬に関連する副作用
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 統合失調症治療薬市場セラピークラス別

  • 第2世代
  • 第三世代

第7章 統合失調症治療薬市場行政別

  • 注射可能
  • オーラル

第8章 統合失調症治療薬市場：流通チャネル別

  • 病院
  • 薬局
    • オフライン
    • オンライン

第9章 南北アメリカの統合失調症治療薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の統合失調症治療薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの統合失調症治療薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第13章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Acadia Pharmaceuticals Inc.
    • Alkermes Plc
    • Allergan Plc by AbbVie Inc.
    • Amneal Pharmaceuticals, LLC
    • Astellas Pharma Inc.
    • AstraZeneca plc
    • BioXcel Therapeutics, Inc.
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb and Company
    • Delpor, Inc.
    • Eli Lilly and Company
    • Gedeon Richter Plc
    • Johnson & Johnson Services, Inc.
    • Karuna Therapeutics Inc
    • Lundbeck A/S
    • Luye Pharma Group Ltd
    • Lyndra Therapeutics Inc
    • Meiji Holdings Co., Ltd.
    • Neurocrine Biosciences, Inc.
    • Otsuka America Pharmaceutical Inc.
    • Pfizer Inc.
    • Reviva Pharmaceuticals Holdings, Inc.
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Takeda Pharmaceutical Company Limited
    • Vanda Pharmaceuticals Inc.
  • 主要な製品ポートフォリオ

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. SCHIZOPHRENIA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. SCHIZOPHRENIA THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
  • FIGURE 8. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. SCHIZOPHRENIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. SCHIZOPHRENIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. SCHIZOPHRENIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 6. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 9. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 12. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 15. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 56. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 60. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 64. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 68. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 72. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 76. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 80. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 84. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 88. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 92. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 101. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 105. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 109. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 113. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 117. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 121. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 125. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 129. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 133. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 137. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 141. POLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. POLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. POLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 145. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 149. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 153. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 157. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 161. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 165. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 166. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 169. SWITZERLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. SWITZERLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. SWITZERLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 173. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 177. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 185. SCHIZOPHRENIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 186. SCHIZOPHRENIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 187. SCHIZOPHRENIA THERAPEUTICS MARKET LICENSE & PRICING
目次
Product Code: MRR-8E22B61932E6

[192 Pages Report] The Schizophrenia Therapeutics Market size was estimated at USD 7.89 billion in 2023 and expected to reach USD 8.08 billion in 2024, at a CAGR 4.94% to reach USD 11.06 billion by 2030.

Global Schizophrenia Therapeutics Market

KEY MARKET STATISTICS
Base Year [2023] USD 7.89 billion
Estimated Year [2024] USD 8.08 billion
Forecast Year [2030] USD 11.06 billion
CAGR (%) 4.94%
Schizophrenia Therapeutics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Schizophrenia Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Schizophrenia Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Schizophrenia Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Acadia Pharmaceuticals Inc., Alkermes Plc, Allergan Plc by AbbVie Inc., Amneal Pharmaceuticals, LLC, Astellas Pharma Inc., AstraZeneca plc, BioXcel Therapeutics, Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb and Company, Delpor, Inc., Eli Lilly and Company, Gedeon Richter Plc, Johnson & Johnson Services, Inc., Karuna Therapeutics Inc, Lundbeck A/S, Luye Pharma Group Ltd, Lyndra Therapeutics Inc, Meiji Holdings Co., Ltd., Neurocrine Biosciences, Inc., Otsuka America Pharmaceutical Inc., Pfizer Inc., Reviva Pharmaceuticals Holdings, Inc., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, and Vanda Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the Schizophrenia Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Therapeutic Class
    • Second Generation
    • Third Generation
  • Administration
    • Injectable
    • Oral
  • Distribution Channel
    • Hospital
    • Pharmacies
      • Offline
      • Online
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Schizophrenia Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Schizophrenia Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Schizophrenia Therapeutics Market?

4. What is the market share of the leading vendors in the Schizophrenia Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Schizophrenia Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Schizophrenia Therapeutics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of schizophrenia disorder among individuals worldwide
      • 5.1.1.2. Government initiatives and campaigns to raise awareness regarding mental health conditions
      • 5.1.1.3. Ongoing research for the development of efficient drugs for schizophrenia
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment and lack of insurance coverage
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing focus on personalized medicine for improving drug efficacy in patients with schizophrenia disorder
      • 5.1.3.2. Advancements in schizophrenia treatment and therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with the medications prescribed for schizophrenia
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Schizophrenia Therapeutics Market, by Therapeutic Class

  • 6.1. Introduction
  • 6.2. Second Generation
  • 6.3. Third Generation

7. Schizophrenia Therapeutics Market, by Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral

8. Schizophrenia Therapeutics Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital
  • 8.3. Pharmacies
    • 8.4.1. Offline
    • 8.4.2. Online

9. Americas Schizophrenia Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Schizophrenia Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Schizophrenia Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Acadia Pharmaceuticals Inc.
    • 13.1.2. Alkermes Plc
    • 13.1.3. Allergan Plc by AbbVie Inc.
    • 13.1.4. Amneal Pharmaceuticals, LLC
    • 13.1.5. Astellas Pharma Inc.
    • 13.1.6. AstraZeneca plc
    • 13.1.7. BioXcel Therapeutics, Inc.
    • 13.1.8. Boehringer Ingelheim International GmbH
    • 13.1.9. Bristol-Myers Squibb and Company
    • 13.1.10. Delpor, Inc.
    • 13.1.11. Eli Lilly and Company
    • 13.1.12. Gedeon Richter Plc
    • 13.1.13. Johnson & Johnson Services, Inc.
    • 13.1.14. Karuna Therapeutics Inc
    • 13.1.15. Lundbeck A/S
    • 13.1.16. Luye Pharma Group Ltd
    • 13.1.17. Lyndra Therapeutics Inc
    • 13.1.18. Meiji Holdings Co., Ltd.
    • 13.1.19. Neurocrine Biosciences, Inc.
    • 13.1.20. Otsuka America Pharmaceutical Inc.
    • 13.1.21. Pfizer Inc.
    • 13.1.22. Reviva Pharmaceuticals Holdings, Inc.
    • 13.1.23. Sumitomo Dainippon Pharma Co., Ltd.
    • 13.1.24. Takeda Pharmaceutical Company Limited
    • 13.1.25. Vanda Pharmaceuticals Inc.
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing